SlideShare a Scribd company logo
1 of 22
A comparison of outcomes from in vitro fertilization cycles stimulated 
with either recombinant luteinizing hormone (LH) or human 
chorionic gonadotropin acting as an LH analogue delivered as 
human menopausal gonadotropins, in subjects with good or poor 
ovarian reserve: A retrospective analysis 
Michael H. Dahan *, Mohammed Agdi, Fady Shehata, WeonYoung Son, Seang Lin Tan 
McGill Reproductive Center, McGill University, Royal Victoria Hospital, Montreal, Canada 
European Journal of Obstetrics & Gynecology and Reproductive Biology 172 (2014) 70–73 
Anna Hnug 
Product Manager 
Feb 17th, 2014
Background information 
- Addition of LH may benefit certain patients 
有些特性的病人加入LH後可以 
促進濾泡發育(folliculargenesis) 
及增加懷孕率 
• 年齡較大(>35 yr) 
• Poor responder 
• Very low serum LH level 
在幾個meta-analysis中可看到, 
LH+FSH的protocol比FSH 
alone的protocol 
• 懷孕率較高 
• 臨床懷孕率較高 
• 活產率較高 
• 著床率較高(r-hLH) 
• 使用FSH的劑量較少(agonist 
long protocol) 
• 取得較多的卵(antagonist 
protocol)
LH & follicle maturation 
雖然LH level在late follicular phase才昇高,但在early & mid follicular 
phase時LH有助於濾泡成熟( &selection of dominant follicle)
Background information: r-hLH vs. hMG
探討問題 
需要LH的IVF病人 
-包括卵巢庫存量較少且使用microdose 
flair protocol的IVF病人族群 
r-hLH hMG 
何者效果較佳?
Materials & Methods - medications 
單一中心回溯性研究 
Patients undergoing IVF 
•Including: 
- Received FSH and either r-hLH 
or HMG (not both) 
•Excluding: 
-Thyroid abnormalities 
-Hyperprolactinemia 
-Hypothalamic pituitary 
dysfunction 
-Ovarian failure 
n=105 
r-FSH (Gonal-f) + 
r-hLH (Luveris) 
r-FSH (Gonal-f/Puregon)/urofollitropin + 
hMG (Repronex*) 
2-year period n=96 
Total n=201 
Indicators include: 
Total FSH dose Oocytes obtained Pregnancy rate 
Total LH dose Embryos obtained Clinical pregnancy rate 
* Repronex: Ferring Inc. North York , Canada)
Materials & Methods - protocols 
n=122 
Good ovarian reserve 
baseline FSH <10 IU/L 
and 
baseline AFC ≧6 
Poor ovarian reserve 
baseline FSH≧10 IU/L 
or 
baseline AFC < 6 
n=79 
GnRH agonist long protocol 
112.5~225 IU/daily 
*Microdose flair protocol 
n=105 
r-FSH (Gonal-f) + 
r-hLH (Luveris) 
r-FSH/urofollitropin + 
hMG (Repronex) 
n=96 
• Trigger: 10,000IU or 5,000IU hCG 
• Retrieval & ET: 
17 gauge single lumen needle or 
16 gauge double lumen flushing needle 
300~600 IU/daily 
*Microdose flair protocol
Results (Table 1) 
Patient demographics 兩組相當 
Recombinant 
h-LH 
hMG p-value 
Number of cycles 105 96 – 
Age (years) 36.2 ± 4.1 36.7 ± 4.4 0.39 
Day 3 serum FSH (IU/L) 9.3 ± 7.4 8.9 ± 3.3 0.57 
Day 3 serum estradiol (pmol/L) 180 ± 98 200 ± 118 0.22 
Antral follicle count 14 ± 10 12 ± 7 0.11 
Previous pregnancies 0.8 ± 1.1 1.0 ± 1.1 0.18 
Previous full term pregnancies 0.2 ± 0.5 0.26 ± 0.7 0.22 
Previous miscarriages 0.6 ± 0.9 0.7 ± 0.8 0.40
Results (Table 2) 
Infertility原因僅tubal disease有顯著差異 
Infertility diagnosis r-hLH group hMG group p-value 
Number of cycles 105 96 – 
Male factor 50% 42% 0.24 
Endometriosis 8% 13% 0.24 
Genetic disease carrier 5% 9% 0.30 
PCOS 7% 1% 0.10 
Tubal disease 7% 17% 0.02* 
Unexplained 28% 23% 0.38 
*Since patients may have more that one infertility diagnosis, the diagnostic rates total >100%.
Results (Table 3) 
IVF treatment outcomes 比較 
r-hLH hMG p-value Comments (r-hLH組) 
Number of cycles 105 96 – 
Total FSH dose (IU) 3944 ± 1820 4783 ± 2100 0.003* 使用較少的FSH 
Total LH dose (IU) 1601 ± 952 2354 ± 1784 0.0001* 使用較少的LH 
Oocytes obtained 12 ± 7 10 ± 6 0.008* 得到較多的卵 
Embryos obtained 7 ± 5 5 ± 3 0.009* 得到較多的胚胎 
Percent of ICSI cases per group 75% 82% 0.23 
Pregnancy rate per cycle start 42% 26% 0.03* 較高的懷孕率 
Clinical pregnancy rate, per cycle 
start 
36% 20% 0.02* 較高的臨床懷孕率
Results (Table 4) 
依照卵巢庫存量指標比較r-hLH vs. hMG有無顯著差異(p-value) 
good good poor poor 
Baseline FSH 
<10 IU/L 
Baseline 
AFC ≥ 6 
Baseline FSH 
≥10 IU/L 
Baseline AFC 
<6 
r-hLH (n) 78 88 27 17 
hMG (n) 68 82 28 14 
Total FSH dose (IU) 較少0.003* 0.002* 0.35 0.15 
Total LH dose (IU) 較少0.001* 0.001* 0.09 0.21 
Oocytes obtained 較多0.01* 0.002* 0.33 0.44 
Embryos obtained 較多0.03* 0.007* 0.16 0.63 
Pregnancy 較高0.12 0.01* 0.15 1.0 
Clinical pregnancy 較高0.18 0.02* 0.04* 1.0 
•在good ovarian reserve (FSH < 10IU/L ; AFC ≥ 6)的病人, 
r-hLH gr.的表現顯著優於HMG(取得較多卵、較高懷孕率)
Recombinant human LH supplementation versus 
supplementation with urinary hCG-based LH activity during 
controlled ovarian stimulation in the long GnRH-agonist protocol: a 
matched case–control study 
Klaus F. Bühler1 & Robert Fischer2 
1Kinderwunschzentrum Hanover-Langenhagen & Wolfsburg, GMP Müseler-Albers/Arendt/Bühler/Schill, 
Langenhagen, Germany and 
2Fertility Center Hamburg, Hamburg, Germany 
European Journal of Obstetrics & Gynecology and Reproductive Biology 172 (2014) 70–73
Materials & Methods - medications 
r-hFSH + r-hLH (2:1) 
(n=1573) 
hMG alone 
(n=1573) 
hMG + r-hFSH 
(n=1573) 
long GnRH-agonist protocol 
(n=4719) 
與另兩組相比: 
• r-hFSH使用量較少 
• 懷孕率較高 
• 胚胎植入著床率較高 
• 2007 Oct.~2009 Jun. 
• Data collected using RecDate electronic 
database
Results (Table 1) 
Patient demographics 兩組相當
Results (Table 2) 
r-hLH+r-hFSH gr. FSH 使用劑量顯著較低
Results (Table 3) 
r-hLH+r-hFSH , ≦35 yr sub gr. 的implantation 
rate per ET 顯著較高(24.8% vs. 17.2% & 17.5%)
Discussion 
 The pts population analysed can be regarded as representative for 
routine ART treatment in Germany 
 r-hLH (in combination with r-hFSH) 比u-hMG 的懷孕率顯著較高(per 
cycle and per ET); 著床率顯著較高(per ET) 
 Age subgroup analysis: r-hLH 對於小於35歲的pts, 有較明顯的效益
Information sharing: 
Current standard luteal phase support in 
NTUH
TNUH current standard luteal phase support 
• For fresh IVF cycle, Estrade (2 mg) 3 bid and Crinone 1 bid 
for follicle number > 10 or for all cases 
• For fresh IVF cycle, Utrogestan (100 mg) 1 tid or Crinone 1 qd, 
plus Pregnyl (hCG 1500 IU) q3d, 3 doses, for follicle number < 10 
• For frozen ET with natural cycle, Crinone 1 qd 
• For frozen ET with HRT* cycle, Crinone 1 bid 
* HRT: Hormone Replacement Treatment
Starting time and duration of the luteal phase 
support 
• For the fresh IVF cycle, start since 2 days after OPU (2-4 cell stage) 
- After pregnancy test, if the corpus lutein is rescued, stop the LPS gradually. 
- If the corpus lutein is not rescued, continue to GA 12 weeks. 
• For frozen ET with natural cycle, start since 2 days after ovulation (2-4 cell stage). 
- Stop LPS after pregnancy test or continue to GA 7-9 weeks. 
• For HRT cycle, the day of LPS is defined as ovulation day, 
- continue to GA 12 weeks.
Early pregnancy / Extend the luteal support 
• For the fresh IVF cycle, 
- If the corpus lutein is rescued, taper and then stop the LPS at GA 5 weeks. 
-If the corpus lutein is not rescued, continue to GA 12 weeks. 
• For frozen ET with natural cycle, 
- stop LPS after pregnancy test or continue to GA 7-9 weeks. 
• For HRT cycle, continue to GA 12 weeks.
Feedback on Crinone 
• Good results 
• No pain, No dizziness 
• Reduce OHSS 
• Some with itching, not common

More Related Content

What's hot

Ovulation induction protocols for unexplained infertility new advances 2019 f...
Ovulation induction protocols for unexplained infertility new advances 2019 f...Ovulation induction protocols for unexplained infertility new advances 2019 f...
Ovulation induction protocols for unexplained infertility new advances 2019 f...Anu Test Tube Baby Centre
 
On invividualization of ovarian stimulation: the arguments in favor
On invividualization of ovarian stimulation: the arguments in favorOn invividualization of ovarian stimulation: the arguments in favor
On invividualization of ovarian stimulation: the arguments in favorSandro Esteves
 
Individualizing Ovarian Stimulation Protocols for IVF
Individualizing Ovarian Stimulation Protocols for IVFIndividualizing Ovarian Stimulation Protocols for IVF
Individualizing Ovarian Stimulation Protocols for IVFSherInstitute
 
Ovulation Induction in Different Case Scenario- Dr. Kaberi Banerjee
Ovulation Induction in Different Case Scenario- Dr. Kaberi BanerjeeOvulation Induction in Different Case Scenario- Dr. Kaberi Banerjee
Ovulation Induction in Different Case Scenario- Dr. Kaberi BanerjeeKaberi Banerjee
 
L2 alviggi key slides (1)
L2 alviggi key slides (1)L2 alviggi key slides (1)
L2 alviggi key slides (1)t7260678
 
OHSS Management - Dr Dhorepatil Bharati
OHSS Management - Dr Dhorepatil BharatiOHSS Management - Dr Dhorepatil Bharati
OHSS Management - Dr Dhorepatil BharatiBharati Dhorepatil
 
​Is There a Best Stimulation Protocol in OI/IUI Cycles?
​Is There a Best Stimulation Protocol in OI/IUI Cycles?​Is There a Best Stimulation Protocol in OI/IUI Cycles?
​Is There a Best Stimulation Protocol in OI/IUI Cycles?Sandro Esteves
 
Indivisualization of Ovulation Induction - Dr Dhorepatil Bharati
Indivisualization of Ovulation Induction - Dr Dhorepatil BharatiIndivisualization of Ovulation Induction - Dr Dhorepatil Bharati
Indivisualization of Ovulation Induction - Dr Dhorepatil BharatiBharati Dhorepatil
 
Adjuvants in por (1)
Adjuvants in por (1)Adjuvants in por (1)
Adjuvants in por (1)rupalibassi
 
Mild ovarian stimulation in women with poor ovarian reserve (PRIMA)
Mild ovarian stimulation in women with poor ovarian reserve (PRIMA)Mild ovarian stimulation in women with poor ovarian reserve (PRIMA)
Mild ovarian stimulation in women with poor ovarian reserve (PRIMA)IVF-Mohamed Youssef AF
 
ovulation induction protocols update 2014
ovulation induction protocols update 2014ovulation induction protocols update 2014
ovulation induction protocols update 2014Hesham Al-Inany
 
Individualization of Patient Treatment
Individualization of Patient TreatmentIndividualization of Patient Treatment
Individualization of Patient TreatmentSandro Esteves
 
GnRH Agonist vs GnRH Antagonist what to choose?
GnRH Agonist vs GnRH Antagonist what to choose?GnRH Agonist vs GnRH Antagonist what to choose?
GnRH Agonist vs GnRH Antagonist what to choose?DrRitu Santwani
 
Agonists and antagonists in controlled ovarian stimulation
Agonists and antagonists in controlled ovarian stimulationAgonists and antagonists in controlled ovarian stimulation
Agonists and antagonists in controlled ovarian stimulationSandro Esteves
 

What's hot (20)

Ovulation induction protocols for unexplained infertility new advances 2019 f...
Ovulation induction protocols for unexplained infertility new advances 2019 f...Ovulation induction protocols for unexplained infertility new advances 2019 f...
Ovulation induction protocols for unexplained infertility new advances 2019 f...
 
On invividualization of ovarian stimulation: the arguments in favor
On invividualization of ovarian stimulation: the arguments in favorOn invividualization of ovarian stimulation: the arguments in favor
On invividualization of ovarian stimulation: the arguments in favor
 
High responders
High respondersHigh responders
High responders
 
GnRH antagonists
GnRH antagonistsGnRH antagonists
GnRH antagonists
 
Brijuni
BrijuniBrijuni
Brijuni
 
Individualizing Ovarian Stimulation Protocols for IVF
Individualizing Ovarian Stimulation Protocols for IVFIndividualizing Ovarian Stimulation Protocols for IVF
Individualizing Ovarian Stimulation Protocols for IVF
 
Ovulation Induction in Different Case Scenario- Dr. Kaberi Banerjee
Ovulation Induction in Different Case Scenario- Dr. Kaberi BanerjeeOvulation Induction in Different Case Scenario- Dr. Kaberi Banerjee
Ovulation Induction in Different Case Scenario- Dr. Kaberi Banerjee
 
L2 alviggi key slides (1)
L2 alviggi key slides (1)L2 alviggi key slides (1)
L2 alviggi key slides (1)
 
OHSS Management - Dr Dhorepatil Bharati
OHSS Management - Dr Dhorepatil BharatiOHSS Management - Dr Dhorepatil Bharati
OHSS Management - Dr Dhorepatil Bharati
 
Use of GnRH
Use of GnRHUse of GnRH
Use of GnRH
 
GnRH Agonist Versus GnRH Antagonist
GnRH Agonist Versus GnRH AntagonistGnRH Agonist Versus GnRH Antagonist
GnRH Agonist Versus GnRH Antagonist
 
​Is There a Best Stimulation Protocol in OI/IUI Cycles?
​Is There a Best Stimulation Protocol in OI/IUI Cycles?​Is There a Best Stimulation Protocol in OI/IUI Cycles?
​Is There a Best Stimulation Protocol in OI/IUI Cycles?
 
Gn rh
Gn rhGn rh
Gn rh
 
Indivisualization of Ovulation Induction - Dr Dhorepatil Bharati
Indivisualization of Ovulation Induction - Dr Dhorepatil BharatiIndivisualization of Ovulation Induction - Dr Dhorepatil Bharati
Indivisualization of Ovulation Induction - Dr Dhorepatil Bharati
 
Adjuvants in por (1)
Adjuvants in por (1)Adjuvants in por (1)
Adjuvants in por (1)
 
Mild ovarian stimulation in women with poor ovarian reserve (PRIMA)
Mild ovarian stimulation in women with poor ovarian reserve (PRIMA)Mild ovarian stimulation in women with poor ovarian reserve (PRIMA)
Mild ovarian stimulation in women with poor ovarian reserve (PRIMA)
 
ovulation induction protocols update 2014
ovulation induction protocols update 2014ovulation induction protocols update 2014
ovulation induction protocols update 2014
 
Individualization of Patient Treatment
Individualization of Patient TreatmentIndividualization of Patient Treatment
Individualization of Patient Treatment
 
GnRH Agonist vs GnRH Antagonist what to choose?
GnRH Agonist vs GnRH Antagonist what to choose?GnRH Agonist vs GnRH Antagonist what to choose?
GnRH Agonist vs GnRH Antagonist what to choose?
 
Agonists and antagonists in controlled ovarian stimulation
Agonists and antagonists in controlled ovarian stimulationAgonists and antagonists in controlled ovarian stimulation
Agonists and antagonists in controlled ovarian stimulation
 

Viewers also liked

L8 key slides simon
L8 key slides simonL8 key slides simon
L8 key slides simont7260678
 
Other potential definitions of success in art itt, et, (1)
Other potential definitions of success in art itt, et, (1)Other potential definitions of success in art itt, et, (1)
Other potential definitions of success in art itt, et, (1)t7260678
 
Hum. reprod. 2013-enciso-1707-15
Hum. reprod. 2013-enciso-1707-15Hum. reprod. 2013-enciso-1707-15
Hum. reprod. 2013-enciso-1707-15t7260678
 
複製 Embryotransferincattle (1)
複製  Embryotransferincattle (1)複製  Embryotransferincattle (1)
複製 Embryotransferincattle (1)t7260678
 
L3 key slides orvieto
L3 key slides orvietoL3 key slides orvieto
L3 key slides orvietot7260678
 
L10 freour
L10 freourL10 freour
L10 freourt7260678
 
Improved sensitivit
Improved sensitivitImproved sensitivit
Improved sensitivitt7260678
 
Dr. irene souter pgd stickler foundation (7)
Dr. irene souter pgd stickler foundation (7)Dr. irene souter pgd stickler foundation (7)
Dr. irene souter pgd stickler foundation (7)t7260678
 
Dr. irene souter pgd stickler foundation (1)
Dr. irene souter pgd stickler foundation (1)Dr. irene souter pgd stickler foundation (1)
Dr. irene souter pgd stickler foundation (1)t7260678
 
L2 alviggi key slides
L2 alviggi key slidesL2 alviggi key slides
L2 alviggi key slidest7260678
 
Clinical manaement of in vitrofertilizatonwithpreimplantation geneticdiagnosi...
Clinical manaement of in vitrofertilizatonwithpreimplantation geneticdiagnosi...Clinical manaement of in vitrofertilizatonwithpreimplantation geneticdiagnosi...
Clinical manaement of in vitrofertilizatonwithpreimplantation geneticdiagnosi...t7260678
 
Embryo 090423111342-phpapp02 (1)
Embryo 090423111342-phpapp02 (1)Embryo 090423111342-phpapp02 (1)
Embryo 090423111342-phpapp02 (1)t7260678
 
L4 key slides ferlin (1)
L4 key slides ferlin (1)L4 key slides ferlin (1)
L4 key slides ferlin (1)t7260678
 
Clinical manaement of in vitrofertilizatonwithpreimplantation geneticdiagnosi...
Clinical manaement of in vitrofertilizatonwithpreimplantation geneticdiagnosi...Clinical manaement of in vitrofertilizatonwithpreimplantation geneticdiagnosi...
Clinical manaement of in vitrofertilizatonwithpreimplantation geneticdiagnosi...t7260678
 
Implantation receptivity window
Implantation    receptivity  windowImplantation    receptivity  window
Implantation receptivity windowt7260678
 
Daganasrm2009abstracto268 12564089438001-phpapp02 (1)
Daganasrm2009abstracto268 12564089438001-phpapp02 (1)Daganasrm2009abstracto268 12564089438001-phpapp02 (1)
Daganasrm2009abstracto268 12564089438001-phpapp02 (1)t7260678
 
Moralthinking1012 7
Moralthinking1012 7Moralthinking1012 7
Moralthinking1012 7t7260678
 
L7 sunkara key slidespptx (1)
L7 sunkara key slidespptx (1)L7 sunkara key slidespptx (1)
L7 sunkara key slidespptx (1)t7260678
 
Ethical issues-in-genetics-and-preimplantation-genetic-diagnosis4633
Ethical issues-in-genetics-and-preimplantation-genetic-diagnosis4633Ethical issues-in-genetics-and-preimplantation-genetic-diagnosis4633
Ethical issues-in-genetics-and-preimplantation-genetic-diagnosis4633t7260678
 

Viewers also liked (20)

L8 key slides simon
L8 key slides simonL8 key slides simon
L8 key slides simon
 
Other potential definitions of success in art itt, et, (1)
Other potential definitions of success in art itt, et, (1)Other potential definitions of success in art itt, et, (1)
Other potential definitions of success in art itt, et, (1)
 
Hum. reprod. 2013-enciso-1707-15
Hum. reprod. 2013-enciso-1707-15Hum. reprod. 2013-enciso-1707-15
Hum. reprod. 2013-enciso-1707-15
 
複製 Embryotransferincattle (1)
複製  Embryotransferincattle (1)複製  Embryotransferincattle (1)
複製 Embryotransferincattle (1)
 
L3 key slides orvieto
L3 key slides orvietoL3 key slides orvieto
L3 key slides orvieto
 
L10 freour
L10 freourL10 freour
L10 freour
 
Improved sensitivit
Improved sensitivitImproved sensitivit
Improved sensitivit
 
Dr. irene souter pgd stickler foundation (7)
Dr. irene souter pgd stickler foundation (7)Dr. irene souter pgd stickler foundation (7)
Dr. irene souter pgd stickler foundation (7)
 
Dr. irene souter pgd stickler foundation (1)
Dr. irene souter pgd stickler foundation (1)Dr. irene souter pgd stickler foundation (1)
Dr. irene souter pgd stickler foundation (1)
 
L1
L1L1
L1
 
L2 alviggi key slides
L2 alviggi key slidesL2 alviggi key slides
L2 alviggi key slides
 
Clinical manaement of in vitrofertilizatonwithpreimplantation geneticdiagnosi...
Clinical manaement of in vitrofertilizatonwithpreimplantation geneticdiagnosi...Clinical manaement of in vitrofertilizatonwithpreimplantation geneticdiagnosi...
Clinical manaement of in vitrofertilizatonwithpreimplantation geneticdiagnosi...
 
Embryo 090423111342-phpapp02 (1)
Embryo 090423111342-phpapp02 (1)Embryo 090423111342-phpapp02 (1)
Embryo 090423111342-phpapp02 (1)
 
L4 key slides ferlin (1)
L4 key slides ferlin (1)L4 key slides ferlin (1)
L4 key slides ferlin (1)
 
Clinical manaement of in vitrofertilizatonwithpreimplantation geneticdiagnosi...
Clinical manaement of in vitrofertilizatonwithpreimplantation geneticdiagnosi...Clinical manaement of in vitrofertilizatonwithpreimplantation geneticdiagnosi...
Clinical manaement of in vitrofertilizatonwithpreimplantation geneticdiagnosi...
 
Implantation receptivity window
Implantation    receptivity  windowImplantation    receptivity  window
Implantation receptivity window
 
Daganasrm2009abstracto268 12564089438001-phpapp02 (1)
Daganasrm2009abstracto268 12564089438001-phpapp02 (1)Daganasrm2009abstracto268 12564089438001-phpapp02 (1)
Daganasrm2009abstracto268 12564089438001-phpapp02 (1)
 
Moralthinking1012 7
Moralthinking1012 7Moralthinking1012 7
Moralthinking1012 7
 
L7 sunkara key slidespptx (1)
L7 sunkara key slidespptx (1)L7 sunkara key slidespptx (1)
L7 sunkara key slidespptx (1)
 
Ethical issues-in-genetics-and-preimplantation-genetic-diagnosis4633
Ethical issues-in-genetics-and-preimplantation-genetic-diagnosis4633Ethical issues-in-genetics-and-preimplantation-genetic-diagnosis4633
Ethical issues-in-genetics-and-preimplantation-genetic-diagnosis4633
 

Similar to 20140217 博元_r_lh vs hmg&crinone (2)

ovarian stimulation : a 2018 update
ovarian stimulation : a 2018 updateovarian stimulation : a 2018 update
ovarian stimulation : a 2018 updateHesham Al-Inany
 
GnRH Agonist vs GnRH Antagonist what to choose?
GnRH Agonist vs GnRH Antagonist what to choose?  GnRH Agonist vs GnRH Antagonist what to choose?
GnRH Agonist vs GnRH Antagonist what to choose? DrRitu Santwani
 
Ovarian Stimulation Protocols
Ovarian Stimulation ProtocolsOvarian Stimulation Protocols
Ovarian Stimulation ProtocolsHesham Gaber
 
Which type of Gonadotrophins should we use for ovarian stimulation in IVF?
Which type of Gonadotrophins should we use for ovarian stimulation in IVF?Which type of Gonadotrophins should we use for ovarian stimulation in IVF?
Which type of Gonadotrophins should we use for ovarian stimulation in IVF?Hesham Al-Inany
 
Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...
Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...
Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...Sandro Esteves
 
Worse pregnancy outcomes with low dose human chorionic
Worse pregnancy outcomes with low dose human chorionicWorse pregnancy outcomes with low dose human chorionic
Worse pregnancy outcomes with low dose human chorionicLaith Alasadi
 
To pill or not to pill in GnRa-antagonist protocols Candido Tomás, Ovumia 030...
To pill or not to pill in GnRa-antagonist protocols Candido Tomás, Ovumia 030...To pill or not to pill in GnRa-antagonist protocols Candido Tomás, Ovumia 030...
To pill or not to pill in GnRa-antagonist protocols Candido Tomás, Ovumia 030...Candido Tomás
 
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil Bharati
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil BharatiOvulation Stimulation Protocols for IUI - Dr Dhorepatil Bharati
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil BharatiBharati Dhorepatil
 
Ovulation Stimulation Protocols for IUI
Ovulation Stimulation Protocols for IUIOvulation Stimulation Protocols for IUI
Ovulation Stimulation Protocols for IUIBharati Dhorepatil
 
Stimulation protocol in ART: should we tailor it on AMH level?
Stimulation protocol in ART: should we tailor it on AMH level?Stimulation protocol in ART: should we tailor it on AMH level?
Stimulation protocol in ART: should we tailor it on AMH level?DrRokeyaBegum
 
Role of LH supplementation in reproductive medicine - Aspire 2013
Role of LH supplementation in reproductive medicine - Aspire 2013Role of LH supplementation in reproductive medicine - Aspire 2013
Role of LH supplementation in reproductive medicine - Aspire 2013Sankalp Singh
 
#Individualization of #cos to #optimize #success
#Individualization of #cos to #optimize #success#Individualization of #cos to #optimize #success
#Individualization of #cos to #optimize #successDr. Abha Majumdar
 
Ov Function Shoham
Ov Function ShohamOv Function Shoham
Ov Function Shohamguest7f0a3a
 
Ov Function Shoham
Ov Function ShohamOv Function Shoham
Ov Function Shohamguest7f0a3a
 
Ov Function Shoham (1)
Ov Function Shoham (1)Ov Function Shoham (1)
Ov Function Shoham (1)guest7f0a3a
 
Poor response in IVF : How to manage : 2018
Poor response in IVF : How to manage : 2018Poor response in IVF : How to manage : 2018
Poor response in IVF : How to manage : 2018Hesham Al-Inany
 

Similar to 20140217 博元_r_lh vs hmg&crinone (2) (20)

Effective Safe Superovulation.
Effective Safe Superovulation.Effective Safe Superovulation.
Effective Safe Superovulation.
 
ovarian stimulation : a 2018 update
ovarian stimulation : a 2018 updateovarian stimulation : a 2018 update
ovarian stimulation : a 2018 update
 
Adjuvant therapy
Adjuvant therapyAdjuvant therapy
Adjuvant therapy
 
GnRH Agonist vs GnRH Antagonist what to choose?
GnRH Agonist vs GnRH Antagonist what to choose?  GnRH Agonist vs GnRH Antagonist what to choose?
GnRH Agonist vs GnRH Antagonist what to choose?
 
Ovarian Stimulation Protocols
Ovarian Stimulation ProtocolsOvarian Stimulation Protocols
Ovarian Stimulation Protocols
 
Which type of Gonadotrophins should we use for ovarian stimulation in IVF?
Which type of Gonadotrophins should we use for ovarian stimulation in IVF?Which type of Gonadotrophins should we use for ovarian stimulation in IVF?
Which type of Gonadotrophins should we use for ovarian stimulation in IVF?
 
Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...
Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...
Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...
 
Ovarian hyper stimulation syndrome ohss
Ovarian hyper stimulation syndrome ohssOvarian hyper stimulation syndrome ohss
Ovarian hyper stimulation syndrome ohss
 
Worse pregnancy outcomes with low dose human chorionic
Worse pregnancy outcomes with low dose human chorionicWorse pregnancy outcomes with low dose human chorionic
Worse pregnancy outcomes with low dose human chorionic
 
To pill or not to pill in GnRa-antagonist protocols Candido Tomás, Ovumia 030...
To pill or not to pill in GnRa-antagonist protocols Candido Tomás, Ovumia 030...To pill or not to pill in GnRa-antagonist protocols Candido Tomás, Ovumia 030...
To pill or not to pill in GnRa-antagonist protocols Candido Tomás, Ovumia 030...
 
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil Bharati
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil BharatiOvulation Stimulation Protocols for IUI - Dr Dhorepatil Bharati
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil Bharati
 
Ovulation Stimulation Protocols for IUI
Ovulation Stimulation Protocols for IUIOvulation Stimulation Protocols for IUI
Ovulation Stimulation Protocols for IUI
 
Stimulation protocol in ART: should we tailor it on AMH level?
Stimulation protocol in ART: should we tailor it on AMH level?Stimulation protocol in ART: should we tailor it on AMH level?
Stimulation protocol in ART: should we tailor it on AMH level?
 
Role of LH supplementation in reproductive medicine - Aspire 2013
Role of LH supplementation in reproductive medicine - Aspire 2013Role of LH supplementation in reproductive medicine - Aspire 2013
Role of LH supplementation in reproductive medicine - Aspire 2013
 
O.i 2021
O.i 2021O.i 2021
O.i 2021
 
#Individualization of #cos to #optimize #success
#Individualization of #cos to #optimize #success#Individualization of #cos to #optimize #success
#Individualization of #cos to #optimize #success
 
Ov Function Shoham
Ov Function ShohamOv Function Shoham
Ov Function Shoham
 
Ov Function Shoham
Ov Function ShohamOv Function Shoham
Ov Function Shoham
 
Ov Function Shoham (1)
Ov Function Shoham (1)Ov Function Shoham (1)
Ov Function Shoham (1)
 
Poor response in IVF : How to manage : 2018
Poor response in IVF : How to manage : 2018Poor response in IVF : How to manage : 2018
Poor response in IVF : How to manage : 2018
 

More from t7260678

Newdevelopment
NewdevelopmentNewdevelopment
Newdevelopmentt7260678
 
Embryology (mo)
Embryology (mo)Embryology (mo)
Embryology (mo)t7260678
 
04 implantation
04 implantation04 implantation
04 implantationt7260678
 
Munnearraycghupdate201005 12736039844094-phpapp02 (1)
Munnearraycghupdate201005 12736039844094-phpapp02 (1)Munnearraycghupdate201005 12736039844094-phpapp02 (1)
Munnearraycghupdate201005 12736039844094-phpapp02 (1)t7260678
 
Human embryonic development
Human embryonic developmentHuman embryonic development
Human embryonic developmentt7260678
 
Recurent art failure_in_evidence_based_medicine_embryologist_perspective
Recurent art failure_in_evidence_based_medicine_embryologist_perspectiveRecurent art failure_in_evidence_based_medicine_embryologist_perspective
Recurent art failure_in_evidence_based_medicine_embryologist_perspectivet7260678
 
2a embryonic development
2a embryonic development2a embryonic development
2a embryonic developmentt7260678
 
Implantation of embryo 3
Implantation of embryo 3Implantation of embryo 3
Implantation of embryo 3t7260678
 
Munneasrm2009abstracto6 12564080005062-phpapp03
Munneasrm2009abstracto6 12564080005062-phpapp03Munneasrm2009abstracto6 12564080005062-phpapp03
Munneasrm2009abstracto6 12564080005062-phpapp03t7260678
 
Daganasrm2009abstracto268 12564089438001-phpapp02
Daganasrm2009abstracto268 12564089438001-phpapp02Daganasrm2009abstracto268 12564089438001-phpapp02
Daganasrm2009abstracto268 12564089438001-phpapp02t7260678
 
Munneoverviewpgdchina200911withsound 12588814598727-phpapp02
Munneoverviewpgdchina200911withsound 12588814598727-phpapp02Munneoverviewpgdchina200911withsound 12588814598727-phpapp02
Munneoverviewpgdchina200911withsound 12588814598727-phpapp02t7260678
 
Mjd presentation1 (1)
Mjd presentation1 (1)Mjd presentation1 (1)
Mjd presentation1 (1)t7260678
 
Embryotransferincattle
EmbryotransferincattleEmbryotransferincattle
Embryotransferincattlet7260678
 
Power point
Power pointPower point
Power pointt7260678
 
Embryo transfer in_cattle
Embryo transfer in_cattleEmbryo transfer in_cattle
Embryo transfer in_cattlet7260678
 
Embryo 090423111342-phpapp02
Embryo 090423111342-phpapp02Embryo 090423111342-phpapp02
Embryo 090423111342-phpapp02t7260678
 
Embryo transfer
Embryo transferEmbryo transfer
Embryo transfert7260678
 
Power point (1)
Power point (1)Power point (1)
Power point (1)t7260678
 
複製 Embryo-090423111342-phpapp02 (1)
複製  Embryo-090423111342-phpapp02 (1)複製  Embryo-090423111342-phpapp02 (1)
複製 Embryo-090423111342-phpapp02 (1)t7260678
 
Munneoverviewpgdchina200911withsound 12588814598727-phpapp02 (1)
Munneoverviewpgdchina200911withsound 12588814598727-phpapp02 (1)Munneoverviewpgdchina200911withsound 12588814598727-phpapp02 (1)
Munneoverviewpgdchina200911withsound 12588814598727-phpapp02 (1)t7260678
 

More from t7260678 (20)

Newdevelopment
NewdevelopmentNewdevelopment
Newdevelopment
 
Embryology (mo)
Embryology (mo)Embryology (mo)
Embryology (mo)
 
04 implantation
04 implantation04 implantation
04 implantation
 
Munnearraycghupdate201005 12736039844094-phpapp02 (1)
Munnearraycghupdate201005 12736039844094-phpapp02 (1)Munnearraycghupdate201005 12736039844094-phpapp02 (1)
Munnearraycghupdate201005 12736039844094-phpapp02 (1)
 
Human embryonic development
Human embryonic developmentHuman embryonic development
Human embryonic development
 
Recurent art failure_in_evidence_based_medicine_embryologist_perspective
Recurent art failure_in_evidence_based_medicine_embryologist_perspectiveRecurent art failure_in_evidence_based_medicine_embryologist_perspective
Recurent art failure_in_evidence_based_medicine_embryologist_perspective
 
2a embryonic development
2a embryonic development2a embryonic development
2a embryonic development
 
Implantation of embryo 3
Implantation of embryo 3Implantation of embryo 3
Implantation of embryo 3
 
Munneasrm2009abstracto6 12564080005062-phpapp03
Munneasrm2009abstracto6 12564080005062-phpapp03Munneasrm2009abstracto6 12564080005062-phpapp03
Munneasrm2009abstracto6 12564080005062-phpapp03
 
Daganasrm2009abstracto268 12564089438001-phpapp02
Daganasrm2009abstracto268 12564089438001-phpapp02Daganasrm2009abstracto268 12564089438001-phpapp02
Daganasrm2009abstracto268 12564089438001-phpapp02
 
Munneoverviewpgdchina200911withsound 12588814598727-phpapp02
Munneoverviewpgdchina200911withsound 12588814598727-phpapp02Munneoverviewpgdchina200911withsound 12588814598727-phpapp02
Munneoverviewpgdchina200911withsound 12588814598727-phpapp02
 
Mjd presentation1 (1)
Mjd presentation1 (1)Mjd presentation1 (1)
Mjd presentation1 (1)
 
Embryotransferincattle
EmbryotransferincattleEmbryotransferincattle
Embryotransferincattle
 
Power point
Power pointPower point
Power point
 
Embryo transfer in_cattle
Embryo transfer in_cattleEmbryo transfer in_cattle
Embryo transfer in_cattle
 
Embryo 090423111342-phpapp02
Embryo 090423111342-phpapp02Embryo 090423111342-phpapp02
Embryo 090423111342-phpapp02
 
Embryo transfer
Embryo transferEmbryo transfer
Embryo transfer
 
Power point (1)
Power point (1)Power point (1)
Power point (1)
 
複製 Embryo-090423111342-phpapp02 (1)
複製  Embryo-090423111342-phpapp02 (1)複製  Embryo-090423111342-phpapp02 (1)
複製 Embryo-090423111342-phpapp02 (1)
 
Munneoverviewpgdchina200911withsound 12588814598727-phpapp02 (1)
Munneoverviewpgdchina200911withsound 12588814598727-phpapp02 (1)Munneoverviewpgdchina200911withsound 12588814598727-phpapp02 (1)
Munneoverviewpgdchina200911withsound 12588814598727-phpapp02 (1)
 

20140217 博元_r_lh vs hmg&crinone (2)

  • 1. A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: A retrospective analysis Michael H. Dahan *, Mohammed Agdi, Fady Shehata, WeonYoung Son, Seang Lin Tan McGill Reproductive Center, McGill University, Royal Victoria Hospital, Montreal, Canada European Journal of Obstetrics & Gynecology and Reproductive Biology 172 (2014) 70–73 Anna Hnug Product Manager Feb 17th, 2014
  • 2. Background information - Addition of LH may benefit certain patients 有些特性的病人加入LH後可以 促進濾泡發育(folliculargenesis) 及增加懷孕率 • 年齡較大(>35 yr) • Poor responder • Very low serum LH level 在幾個meta-analysis中可看到, LH+FSH的protocol比FSH alone的protocol • 懷孕率較高 • 臨床懷孕率較高 • 活產率較高 • 著床率較高(r-hLH) • 使用FSH的劑量較少(agonist long protocol) • 取得較多的卵(antagonist protocol)
  • 3. LH & follicle maturation 雖然LH level在late follicular phase才昇高,但在early & mid follicular phase時LH有助於濾泡成熟( &selection of dominant follicle)
  • 5. 探討問題 需要LH的IVF病人 -包括卵巢庫存量較少且使用microdose flair protocol的IVF病人族群 r-hLH hMG 何者效果較佳?
  • 6. Materials & Methods - medications 單一中心回溯性研究 Patients undergoing IVF •Including: - Received FSH and either r-hLH or HMG (not both) •Excluding: -Thyroid abnormalities -Hyperprolactinemia -Hypothalamic pituitary dysfunction -Ovarian failure n=105 r-FSH (Gonal-f) + r-hLH (Luveris) r-FSH (Gonal-f/Puregon)/urofollitropin + hMG (Repronex*) 2-year period n=96 Total n=201 Indicators include: Total FSH dose Oocytes obtained Pregnancy rate Total LH dose Embryos obtained Clinical pregnancy rate * Repronex: Ferring Inc. North York , Canada)
  • 7. Materials & Methods - protocols n=122 Good ovarian reserve baseline FSH <10 IU/L and baseline AFC ≧6 Poor ovarian reserve baseline FSH≧10 IU/L or baseline AFC < 6 n=79 GnRH agonist long protocol 112.5~225 IU/daily *Microdose flair protocol n=105 r-FSH (Gonal-f) + r-hLH (Luveris) r-FSH/urofollitropin + hMG (Repronex) n=96 • Trigger: 10,000IU or 5,000IU hCG • Retrieval & ET: 17 gauge single lumen needle or 16 gauge double lumen flushing needle 300~600 IU/daily *Microdose flair protocol
  • 8. Results (Table 1) Patient demographics 兩組相當 Recombinant h-LH hMG p-value Number of cycles 105 96 – Age (years) 36.2 ± 4.1 36.7 ± 4.4 0.39 Day 3 serum FSH (IU/L) 9.3 ± 7.4 8.9 ± 3.3 0.57 Day 3 serum estradiol (pmol/L) 180 ± 98 200 ± 118 0.22 Antral follicle count 14 ± 10 12 ± 7 0.11 Previous pregnancies 0.8 ± 1.1 1.0 ± 1.1 0.18 Previous full term pregnancies 0.2 ± 0.5 0.26 ± 0.7 0.22 Previous miscarriages 0.6 ± 0.9 0.7 ± 0.8 0.40
  • 9. Results (Table 2) Infertility原因僅tubal disease有顯著差異 Infertility diagnosis r-hLH group hMG group p-value Number of cycles 105 96 – Male factor 50% 42% 0.24 Endometriosis 8% 13% 0.24 Genetic disease carrier 5% 9% 0.30 PCOS 7% 1% 0.10 Tubal disease 7% 17% 0.02* Unexplained 28% 23% 0.38 *Since patients may have more that one infertility diagnosis, the diagnostic rates total >100%.
  • 10. Results (Table 3) IVF treatment outcomes 比較 r-hLH hMG p-value Comments (r-hLH組) Number of cycles 105 96 – Total FSH dose (IU) 3944 ± 1820 4783 ± 2100 0.003* 使用較少的FSH Total LH dose (IU) 1601 ± 952 2354 ± 1784 0.0001* 使用較少的LH Oocytes obtained 12 ± 7 10 ± 6 0.008* 得到較多的卵 Embryos obtained 7 ± 5 5 ± 3 0.009* 得到較多的胚胎 Percent of ICSI cases per group 75% 82% 0.23 Pregnancy rate per cycle start 42% 26% 0.03* 較高的懷孕率 Clinical pregnancy rate, per cycle start 36% 20% 0.02* 較高的臨床懷孕率
  • 11. Results (Table 4) 依照卵巢庫存量指標比較r-hLH vs. hMG有無顯著差異(p-value) good good poor poor Baseline FSH <10 IU/L Baseline AFC ≥ 6 Baseline FSH ≥10 IU/L Baseline AFC <6 r-hLH (n) 78 88 27 17 hMG (n) 68 82 28 14 Total FSH dose (IU) 較少0.003* 0.002* 0.35 0.15 Total LH dose (IU) 較少0.001* 0.001* 0.09 0.21 Oocytes obtained 較多0.01* 0.002* 0.33 0.44 Embryos obtained 較多0.03* 0.007* 0.16 0.63 Pregnancy 較高0.12 0.01* 0.15 1.0 Clinical pregnancy 較高0.18 0.02* 0.04* 1.0 •在good ovarian reserve (FSH < 10IU/L ; AFC ≥ 6)的病人, r-hLH gr.的表現顯著優於HMG(取得較多卵、較高懷孕率)
  • 12. Recombinant human LH supplementation versus supplementation with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol: a matched case–control study Klaus F. Bühler1 & Robert Fischer2 1Kinderwunschzentrum Hanover-Langenhagen & Wolfsburg, GMP Müseler-Albers/Arendt/Bühler/Schill, Langenhagen, Germany and 2Fertility Center Hamburg, Hamburg, Germany European Journal of Obstetrics & Gynecology and Reproductive Biology 172 (2014) 70–73
  • 13. Materials & Methods - medications r-hFSH + r-hLH (2:1) (n=1573) hMG alone (n=1573) hMG + r-hFSH (n=1573) long GnRH-agonist protocol (n=4719) 與另兩組相比: • r-hFSH使用量較少 • 懷孕率較高 • 胚胎植入著床率較高 • 2007 Oct.~2009 Jun. • Data collected using RecDate electronic database
  • 14. Results (Table 1) Patient demographics 兩組相當
  • 15. Results (Table 2) r-hLH+r-hFSH gr. FSH 使用劑量顯著較低
  • 16. Results (Table 3) r-hLH+r-hFSH , ≦35 yr sub gr. 的implantation rate per ET 顯著較高(24.8% vs. 17.2% & 17.5%)
  • 17. Discussion  The pts population analysed can be regarded as representative for routine ART treatment in Germany  r-hLH (in combination with r-hFSH) 比u-hMG 的懷孕率顯著較高(per cycle and per ET); 著床率顯著較高(per ET)  Age subgroup analysis: r-hLH 對於小於35歲的pts, 有較明顯的效益
  • 18. Information sharing: Current standard luteal phase support in NTUH
  • 19. TNUH current standard luteal phase support • For fresh IVF cycle, Estrade (2 mg) 3 bid and Crinone 1 bid for follicle number > 10 or for all cases • For fresh IVF cycle, Utrogestan (100 mg) 1 tid or Crinone 1 qd, plus Pregnyl (hCG 1500 IU) q3d, 3 doses, for follicle number < 10 • For frozen ET with natural cycle, Crinone 1 qd • For frozen ET with HRT* cycle, Crinone 1 bid * HRT: Hormone Replacement Treatment
  • 20. Starting time and duration of the luteal phase support • For the fresh IVF cycle, start since 2 days after OPU (2-4 cell stage) - After pregnancy test, if the corpus lutein is rescued, stop the LPS gradually. - If the corpus lutein is not rescued, continue to GA 12 weeks. • For frozen ET with natural cycle, start since 2 days after ovulation (2-4 cell stage). - Stop LPS after pregnancy test or continue to GA 7-9 weeks. • For HRT cycle, the day of LPS is defined as ovulation day, - continue to GA 12 weeks.
  • 21. Early pregnancy / Extend the luteal support • For the fresh IVF cycle, - If the corpus lutein is rescued, taper and then stop the LPS at GA 5 weeks. -If the corpus lutein is not rescued, continue to GA 12 weeks. • For frozen ET with natural cycle, - stop LPS after pregnancy test or continue to GA 7-9 weeks. • For HRT cycle, continue to GA 12 weeks.
  • 22. Feedback on Crinone • Good results • No pain, No dizziness • Reduce OHSS • Some with itching, not common